Abbvie Inc

NYSE: ABBV
$189.45
-$0.23 (-0.1%)
Closing Price on October 29, 2024

ABBV Articles

The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
The top analyst upgrades, downgrades and other research calls from Thursday include Alphabet, Avon, Bank of America, Intel, Roku, Snap and Western Digital.
Is it finally time to consider the old adage that "nothing lasts forever" for the bull market as we enter 2018? Here are 10 things that could wreck the current bull market in stocks in the coming...
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
AbbVie reported better-than-expected third-quarter before the markets opened on Friday due to strong sales of Humira and Imbruvica.
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for years to come.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.